Syndax Pharmaceuticals (SNDX) Non-Current Assets (2015 - 2026)
Syndax Pharmaceuticals (SNDX) posted quarterly Non-Current Assets of $1.5 million for Q1 2026, down 98.38% year-over-year from $92.0 million in Q1 2025, and down 8.25% quarter-over-quarter from $1.6 million in Q4 2025.
Syndax Pharmaceuticals (SNDX) Non-Current Assets (2015 - 2026) Analysis & Trends
Syndax Pharmaceuticals' Non-Current Assets history runs 12 years deep, the most recent figure standing at $1.5 million for Q1 2026.
- In Q1 2026, Non-Current Assets fell 98.38% year-over-year to $1.5 million; the TTM figure through Mar 2026 stood at $89.6 million (down 64.97% YoY), while the FY2025 annual figure was $1.6 million, down 98.67% from the prior year.
- Non-Current Assets for Q1 2026 stood at $1.5 million, down from $1.6 million in the prior quarter.
- The five-year high for Non-Current Assets was $121.8 million in Q4 2024, with the low at $1.5 million in Q1 2026.
- The 5-year median for Non-Current Assets is $18.3 million (2023), against an average of $32.4 million.
- The sharpest annual moves came in 2022 and 2025: Non-Current Assets soared 2707.54% in 2022, then tumbled 98.67% in 2025.
- Syndax Pharmaceuticals' Non-Current Assets stood at $7.4 million in 2022, then jumped by 329.58% to $32.0 million in 2023, then soared by 280.45% to $121.8 million in 2024, then sank by 98.67% to $1.6 million in 2025, then declined by 8.25% to $1.5 million in 2026.
- Business Quant data shows SNDX's Non-Current Assets at $1.5 million in Q1 2026, $1.6 million in Q4 2025, and $22.0 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 14.88 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 23.28 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.96 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 294.93 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 1.96 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 3.76 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 18.06 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 938.60 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 468.65 Mn |
| 10 | Syndax Pharmaceuticals | 1.77 Bn | 1.22 Bn | 60.67 Mn | 28.61 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 28.61 Mn |
| Mar 31, 2026 | 1.49 Mn |
| Dec 31, 2025 | 1.63 Mn |
| Sep 30, 2025 | 21.96 Mn |
| Jun 30, 2025 | 64.47 Mn |
| Mar 31, 2025 | 91.96 Mn |
| Dec 31, 2024 | 121.76 Mn |
| Sep 30, 2024 | 11.00 Mn |
| Jun 30, 2024 | 30.89 Mn |
| Mar 31, 2024 | 89.13 Mn |
| Dec 31, 2023 | 32.00 Mn |
| Sep 30, 2023 | 18.25 Mn |
| Jun 30, 2023 | 22.26 Mn |
| Mar 31, 2023 | 18.32 Mn |
| Dec 31, 2022 | 7.45 Mn |
| Sep 30, 2022 | 2.06 Mn |
| Jun 30, 2022 | 14.15 Mn |
| Mar 31, 2022 | 2.17 Mn |
| Dec 31, 2021 | 1.26 Mn |
| Sep 30, 2021 | 1.25 Mn |